The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Regeneron Pharmaceuticals Inc

Nasdaq: REGN
Last

(U.S.) $423.79

Today's change+12.80 +3.11%
Updated December 18 4:00 PM EST. Delayed by at least 15 minutes.
 

Regeneron Pharmaceuticals Inc

Nasdaq: REGN
Last

(U.S.) $423.79

Today's change+12.80 +3.11%
Updated December 18 4:00 PM EST. Delayed by at least 15 minutes.

Regeneron Pharmaceuticals Inc crosses above 20-day moving average

Regeneron Pharmaceuticals Inc closed up sharply Thursday, rallying (U.S.)$12.80 or 3.11% to (U.S.)$423.79 and crossing above its 20-day moving average. Over the last five days, shares are unchanged, but are currently 3.16% below its 52-week high. This security has outperformed the S&P 500 by 42.13% during the last year.

Key company metrics

  • Open(U.S.) $415.49
  • Previous close(U.S.) $410.99
  • High(U.S.) $424.44
  • Low(U.S.) $412.40
  • Bid / Ask-- / --
  • YTD % change+53.97%
  • Volume733,769
  • Average volume (10-day)687,013
  • Average volume (1-month)669,314
  • Average volume (3-month)829,823
  • 52-week range(U.S.) $257.69 to (U.S.) $437.64
  • Beta0.85
  • Trailing P/E143.86×
  • P/E 1 year forward41.32×
  • Forward PEG2.04×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $2.95
Updated December 18 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+12.74%

Based on its net profit margin of 12.74%, Regeneron Pharmaceuticals Inc is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.93%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue726666626610
Total other revenue--------
Total revenue726666626610
Gross profit643556545562
Total cost of revenue821108148
Total operating expense543454440398
Selling / general / administrative123397182
Research & development338295287268
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)011----
Other operating expenses, total--------
Operating income183212186212
Interest income (expense), net non-operating-9-10-12-12
Gain (loss) on sale of assets--------
Other--------
Income before tax176203175198
Income after tax80936597
Income tax, total96110110101
Net income80936597
Total adjustments to net income--------
Net income before extra. items80936597
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items80936597
Inc. avail. to common incl. extra. items80936597
Diluted net income83936583
Dilution adjustment300-14
Diluted weighted average shares11711311299
Diluted EPS excluding extraordinary itemsvalue per share0.700.820.580.84
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share0.700.860.580.84